AnaptysBio presents R&D slide deck on PD-1 agonist rosnilimab

ANAPTYSBIO, INC

Presented rosnilimab (PD-1 agonist) R&D slide presentation on October 25, 2023.
No specific clinical data, milestones, or financial guidance disclosed in the filing.
Presentation provided as Exhibit 99.1; not filed, only furnished under Regulation FD.

item 7.01 item 9.01

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-23-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.